Search Results

Deals

Privately-Held NeuroBo Enters Reverse-Merger Deal with Gemphire

Gemphire will enter into the reverse merger following a strategic review of its options.

July 26, 2019

·

3 min read

·

Alex Keown

Deals

Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals

The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions.

December 30, 2019

·

2 min read

Deals

Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals

Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all of the merger-related proposals,

December 6, 2019

·

2 min read

Business

MMS Supported Clinical Data Aspects in Gemphire Therapeutics Meeting its Primary Endpoint in Gemcabene Study

MMS Holdings Inc. announced its integrated support for Gemphire Therapeutics Inc

July 10, 2018

·

3 min read

Drug Development

Gemphire Plunges After Investigational Drug Worsens Liver Fat Levels in Pediatric NAFLD Trial Patients

Shares of Gemphire Therapeutics have crashed 73 percent in premarket trading after the company revealed its mid-stage non-alcoholic fatty liver disease (NAFLD) treatment for pediatric patients actually worsened the disease in some patients.

August 10, 2018

·

2 min read

·

Alex Keown

Deals

NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger

Shares of the Combined Company, NeuroBo Pharmaceuticals, Began Trading on the Nasdaq Exchange Under the Symbol NRBO on December 31, 2019

January 10, 2020

·

7 min read

Drug Development

Gemphire Reports Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting 2017

Gemphire plans to initiate a clinical study in patients suffering from fatty liver disease and NASH in the fourth quarter of 2017.

October 23, 2017

·

7 min read

BioMidwest

Gemphire Announces Proposed Public Offering of Common Stock

The offering is subject to market and other conditions.

February 8, 2018

·

4 min read

Drug Development

Gemphire Provides Clinical Update

January 5, 2017

·

8 min read

Intrexon Enters Into $100M Preferred Stock Equity

BioMidwest

Gemphire Announces Pricing of $22M Public Offering of Common Stock

The company will use the cash from the offering for working capital and general corporate purposes.

February 8, 2018

·

5 min read